ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2015
Novel psychoactive substances of interest for psychiatry.
Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis.Current neuropharmacology · 2025Pooled it
- New Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects.International journal of molecular sciences · 2024Pooled it
- Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants.Frontiers in psychiatry · 2021Pooled it
- Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine.Psychopharmacology · 2018Trial
- The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.Psychopharmacology · 2017Trial
- Human Stem Cell-Derived Neurospheroids and a Multi-Assay Strategy Provide Brain Cytotoxicity New Insights from ADB-FUBIATA Exposure.Neurotoxicity research · 2026Article
- Rapid and Direct Detection of Methamphetamine in Biofluids using a MXene-Enabled Electrochemical Sensor.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Novel Synthetic Opioids (NSOs) and Their Evolving Crisis: Utilising NPSPharmaceuticals (Basel, Switzerland) · 2025Article
- Focus on Cognitive Enhancement: A Narrative Overview of Nootropics and "Smart Drug" Use and Misuse.Biology · 2025Review
- Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues.Brain sciences · 2025Review
- New Synthetic Compounds with Psychoactive Action-Preliminary Results Among Primary and High School Students on the Territory of Novi Sad.Medicines (Basel, Switzerland) · 2025Article
- Xylazine as an emerging new psychoactive substance; focuses on both 5-HTArchiv der Pharmazie · 2025Article
- Clinical and Public Health Challenge of Handling Synthetic Cathinone and Cannabinoid Abuse in Pediatric Care: A Narrative Review.Pediatric reports · 2025Review
- Chemical composition of Ecstasy tablets seized in Poland between 2005 and 2020.Forensic toxicology · 2025Article
- Characterization of the Neurochemical and Behavioral Effects of the Phenethylamine 2-Cl-4,5-MDMA in Adolescent and Adult Male Rats.The international journal of neuropsychopharmacology · 2024Article
- α-Pyrrolidinohexanophenone (α-PHP) and α-Pyrrolidinoisohexanophenone (α-PiHP): A Review.Life (Basel, Switzerland) · 2024Review
- Synthetic cannabinoids awareness among patients with opioid use disorder in Serbia - A survey based cross-sectional pilot study.Frontiers in psychiatry · 2023Article
- Substance use and substance use disorders in Africa: An epidemiological approach to the review of existing literature.World journal of psychiatry · 2022Review
- Analytically confirmed presence of psychoactive substances, especially new psychoactive substances in a group of patients hospitalized with mental and behavioural disorders due to the use of psychoactive substances diagnosis.International journal of occupational medicine and environmental health · 2022Article
- In Vivo Bio-Activation of JWH-175 to JWH-018: Pharmacodynamic and Pharmacokinetic Studies in Mice.International journal of molecular sciences · 2022Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel psychoactive substances include synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a range of prescribed medications, psychoactive plants/herbs, and a large series of performance and image enhancing drugs. Users are typically attracted by these substances due to their intense psychoactive effects and likely lack of detection in routine drug screenings. This paper aims at providing psychiatrists with updated knowledge of the clinical pharmacology and psychopathological consequences of the use of these substances. Indeed, these drugs act on a range of neurotransmitter pathways/receptors whose imbalance has been associated with psychopathological conditions, including dopamine, cannabinoid CB1, GABA-A/B, 5-HT2A, glutamate, and k opioid receptors. An overall approach in terms of clinical management is briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.